Cargando…
Clinical and genomic analysis of baseline and acquired MET fusions with an intact kinase domain in lung cancer patients
Autores principales: | Jin, Bo, Ma, Yutong, Wu, Qian, Ou, Qiuxiang, Shao, Yang, Xu, Shun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Chongqing Medical University
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10425795/ https://www.ncbi.nlm.nih.gov/pubmed/37588206 http://dx.doi.org/10.1016/j.gendis.2023.02.046 |
Ejemplares similares
-
A novel acquired EGFR-SEPT14 fusion confers differential drug resistance to EGFR inhibitors in lung adenocarcinoma
por: Wang, Weidong, et al.
Publicado: (2023) -
Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer
por: Yao, Yu, et al.
Publicado: (2023) -
Intact indoleamine 2,3-dioxygenase activity in human chronic granulomatous disease
por: Jürgens, Birgit, et al.
Publicado: (2010) -
Deletion of Src Homology 3 Domain Results in Constitutive Activation of Tec Protein‐Tyrosine Kinase
por: Yamashita, Yoshihiro, et al.
Publicado: (1996) -
First-in-human phase I study of BPI-9016M, a dual MET/Axl inhibitor, in patients with non-small cell lung cancer
por: Hu, Xingsheng, et al.
Publicado: (2020)